Table 2:
Log10-normalised percentage of peripheral blood plasma ASC specks in patients versus healthy participants
| n | Mean (SD) | Median (IQR) | p value vs normal |
p value vs myelodysplastic syndromes |
p value vs lower-risk |
|
|---|---|---|---|---|---|---|
| Healthy | 29 | −0·67 (0·59) | −0·51 (−0·78 to −0·31) | ·· | 0·034 | 0·0075 |
| Lower-risk myelodysplastic syndromes | 162 | −0·33 (0·42) | −0·33 (−0·65 to −0·10) | 0·0075 | ·· | ·· |
| Higher-risk myelodysplastic syndromes | 15 | −1·18 (0·55) | −1·01 (−1·48 to −0·85) | 0·0073 | ·· | <0·0001 |
| Myelodysplastic syndromes | 177 | −0·41 (0·49) | −0·35 (−0·74 to −0·12) | 0·034 | ·· | ·· |
| Del(5q) | 22 | −1·24 (0·52) | −1·26 (−1·73 to −0·82) | 0·00057 | <0·0001 | <0·0001 |
| Acute lymphocytic leukaemia* | 6 | −1·27 (0·37) | −1·17 (−1·37 to −0·10) | 0·0010 | 0·00030 | <0·0001 |
| Chronic lymphocytic leukaemia | 45 | −1·66 (0·43) | −1·59 (−1·89 to −1·38) | <0·0001 | <0·0001 | <0·0001 |
| Chronic myelogenous leukaemia | 48 | −1·94 (0·65) | −2·05 (−2·43 to −1·54) | <0·0001 | <0·0001 | <0·0001 |
| Chronic myelomonocytic leukaemia | 18 | −1·91 (0·56) | −1·98 (−2·35 to −1·65) | <0·0001 | <0·0001 | <0·0001 |
| De-novo acute myeloid leukaemia | 15 | −1·43 (0·62) | −1·44 (−1·89 to −0·81) | 0·00054 | <0·0001 | <0·0001 |
| Essential thrombocytopenia | 18 | −1·37 (0·72) | −1·19 (−1·71 to −0·90) | 0·0016 | <0·0001 | <0·0001 |
| Large granular lymphocytic leukaemia | 17 | −1·38 (0·57) | −1·39 (−1·80 to −0·95) | 0·00030 | <0·0001 | <0·0001 |
| Myelofibrosis* | 3 | −1·17 (0·98) | −1·64 (−1·73 to −0·84) | 0·46 | 0·19 | 0·15 |
| Multiple myeloma | 18 | −2·02 (0·50) | −2·08 (−2·31 to −1·86) | <0·0001 | <0·0001 | <0·0001 |
| Polycythaemia vera | 18 | −1·56 (0·61) | −1·53 (−1·72 to −1·21) | <0·0001 | <0·0001 | <0·0001 |
| Secondary acute myeloid leukaemia | 24 | −1·48 (0·72) | −1·44 (−2·13 to −1·15) | <0·0001 | <0·0001 | <0·0001 |
| Type 2 diabetes | 23 | −2·09 (0·78) | −2·3 (−2·70 to −1·53) | <0·0001 | <0·0001 | <0·0001 |
| Normal discovery† | 29 | −0·67 (0·59) | −0·51 (−0·78 to −0·31) | ·· | ·· | ·· |
| Normal validation† | 31 | −1·47 (0·52) | −1·49 (−1·86 to −1·15) | ·· | ·· | ·· |
| Myelodysplastic syndromes discovery‡ | 177 | −0·41 (0·49) | −0·35 (−0·74 to −0·12) | ·· | ·· | ·· |
| Myelodysplastic syndromes validation‡ | 113 | −0·56 (0·57) | −0·55 (−0·96 to −0·20) | ·· | ·· | ·· |
ASC=apoptosis-associated speck-like protein containing a CARD. del(5q)=chromosome 5 deletion.
*
p values represent Wilcoxon significance values because of low number of patients.
†
p<0·0001 for patients with myelodysplastic syndromes in the discovery versus validation cohorts.
‡
p=0·02 for healthy controls in the discovery versus validation cohorts.